E-Book

E-Book 3rd Congress

  • Long Non-Coding RNAs (lncRNAs) in Breast Cancer: A Comprehensive Review
  • Fatemeh Ahmadpour,1 Gholamreza Shahsavari,2,* Asma Sepahdar,3 Hadis Rahimi,4 Shadi Nazarifard,5 Mohammad Abbasinasab,6
    1. Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
    2. Department of Clinical Biochemistry, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
    3. Razi Herbal Medicines Research Center Lorestan University of Medical Sciences
    4. Department of Clinical Biochemistry, Lorestan University of Medical Sciences, Khorramabad, Iran
    5. Department of Clinical Biochemistry, Lorestan University of Medical Sciences, Khorramabad, Iran
    6. Department of Clinical Biochemistry, Lorestan University of Medical Sciences, Khorramabad, Iran


  • Introduction: Breast cancer, a heterogeneous disease with diverse molecular subtypes, necessitates a nuanced understanding for improved diagnosis and targeted therapies. This comprehensive review synthesizes findings from multiple studies investigating the role of long non-coding RNAs (lncRNAs) in breast cancer. Ten pertinent studies were examined, elucidating the intricate involvement of various lncRNAs in breast cancer initiation, progression, and prognosis.
  • Methods: A systematic search was conducted across major databases, including PubMed, Scopus, and Web of sciences, covering the period from 2014 to 2023. The primary focus was on identifying studies investigating the role of long non-coding RNAs (lncRNAs) in breast cancer, with an emphasis on their implications as prognostic factors in blood samples.
  • Results: 1. MEG3 rs3087918 and Breast Cancer Risk: • Objective: Explore MEG3 SNPs (rs3087918, rs7158663, rs11160608) in Chinese women. • Findings: rs3087918 associated with decreased breast cancer risk, particularly in women ≤49. Implications for HER-2 receptor expression. Potential structural and miRNA targeting alterations. 2. LncRNA POU3F3 in TNBC: • Objective: Investigate lncRNA POU3F3 in triple-negative breast cancer (TNBC). • Findings: POU3F3 overexpression in TNBC tissues, inversely correlated with cleaved caspase 9. Promotion of cell proliferation and inhibition of apoptosis. Potential therapeutic target. 3. Serum lncRNA TINCR as Prognostic Biomarker in TNBC: • Objective: Assess serum lncRNA TINCR as a prognostic marker in TNBC. • Findings: High circulating TINCR correlated with worse TNBC outcomes. Independent prognostic factor. Non-invasive biomarker potential. 4. LncRNA ZFAS1 Inhibition in TNBC: • Objective: Investigate ZFAS1 expression in TNBC and its impact. • Findings: ZFAS1 downregulated in TNBC, potential tumor suppressor. Inhibition linked to increased cell proliferation. Negative correlation with STAT3. 5. LncRNA RP11-19E11 in Basal Breast Cancer: • Objective: Identify and characterize lncRNA RP11-19E11.1 in basal breast cancers. • Findings: Upregulated in basal primary breast cancers. Chromatin-associated, E2F1 target. Essential for cancer cell proliferation and survival. 6. LncRNA XIST and NEAT1 for High-Risk Breast Cancer Diagnosis: • Objective: Investigate XIST and NEAT1 as diagnostic markers for high-risk breast cancer patients. • Findings: Upregulated in breast cancer patients, correlated with clinicopathological factors. Serum XIST and NEAT1 as non-invasive diagnostic markers. 7. LncRNA-miRNA-mRNA ceRNA Network for Breast Cancer Prognosis: • Objective: Construct ceRNA network for breast cancer prognosis. • Findings: Identification of prognostic factors (ZC3H12B, HRH1, TMEM132C, PAG1). Prognostic risk model accuracy. Insights into potential therapeutic targets. 8. LncRNA NEF in TNBC: • Objective: Investigate lncRNA NEF in TNBC. • Findings: Downregulated in TNBC, inverse correlation with miRNA-155. NEF as a potential tumor suppressor. Implications for prognosis. 9. Serum lncRNA-ATB and FAM83H-AS1 as Breast Cancer Biomarkers: • Objective: Evaluate serum FAM83H-AS1 and lncRNA-ATB as diagnostic/prognostic markers. • Findings: Overexpressed in breast cancer patients. LncRNA-ATB as a superior diagnostic marker. FAM83H-AS1 potential for monitoring progression. 10. LncRNA TCL6 and Immune Infiltration in Breast Cancer: • Objective: Investigate lncRNA TCL6 expression and clinical significance. • Findings: Low TCL6 linked to worse survival, correlation with immune infiltrating cells. Prognostic marker potential.
  • Conclusion: This review underscores the diverse roles of lncRNAs in breast cancer, offering valuable insights into potential diagnostic, prognostic, and therapeutic avenues. The multifaceted interactions between lncRNAs and breast cancer pathogenesis provide a foundation for future research and personalized treatment strategies.
  • Keywords: Breast cancer, Long non-coding RNAs (lncRNAs), Prognostic factors, Blood-based biomarkers, Risk